The influence of 1-β-D-arabinofuranosylcytosine on the metabolism of phosphatidylcholine in human leukemic HL 60 and Raji cells

Leukemia

Volumn 11, Issue 12, 1997, Pages 2079-2086

  Berkovic, D ^a   Fleer, E A M ^a   Breass, J ^a   Pfortner J ^a   Schleyer, E ^a   Hiddemann, W ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

1 D arabinofuranosylcytosine; Membrane phospholipids; Phosphatidylcholine cell lysis

Indexed keywords

CYTARABINE; LYSOPHOSPHATIDYLCHOLINE; MEMBRANE LIPID; MEMBRANE PHOSPHOLIPID; MILTEFOSINE; PHOSPHATIDYLCHOLINE; TRIACYLGLYCEROL;

ARTICLE; BLAST CELL; CELL DEATH; CELL STRAIN HL 60; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG UPTAKE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIPID METABOLISM; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL; RAJI CELL;

EID: 0031453233     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400860     Document Type: Article

References (15)

1. Furth JJ, Cohen S. Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-β-D-arabinofuranosyladenine and the 5′-triphosphate of 9-β-arabinofuranosyladenine. Cancer Res 1969; 28: 2061-2067.
2. Graham FL, Whitemore GF. Studies in mouse L cells in the incorporation of 1-β-D-arabinofuranosylcytosine into DNA and inhibition of DNA polymerase in 1-β-D-arabinofuranosylcytosine 5′triphosphate. Cancer Res 1970; 30: 2636-2644.
3. Kufe DW, Spriggs DR, Egan EM, Munroe D. Relationship among ara-C pools, formation of (ara-C) DNA, and cytotoxicity of human leukemic cells. Blood 1984; 64: 54-58.
4. Spriggs D, Robbins G, Ohno Y, Kufe D. Detection of 1-β-D-arabinofuranosyl cytosine incorporation into DNA in vivo. Cancer Res 1987; 47: 6532-6536.
5. Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S. High dose cytosine arabinosid (HDARAC) in refractory acute leukemia. Cancer 1979; 44: 1189-1193.
6. Herzig RH, Wolff SN, Lazarus HM. High dose cytosine arabinosid therapy for refractory leukemia. Blood 1983; 62: 361-369.
7. Early AP, Preisler HD, Slocum H. A pilot study of high dose 1-β-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res 1982; 42: 1587-1595.
8. Capizzi RL, Poole M, Cooper MR, Richards F II, Stuart JJ, Jackson DV Jr, White DR, Spurr CL, Hopkins JO, Muss HB, Rudnick SA, Wells R, Gabriel D, Ross D. Treatment of poor risk acute leukemia with sequential high dose ara-C and asparaginase. Blood 1984; 63: 694-700.
9. 31P nuclear magnetic resonance study. Cancer Res 1990; 50: 552-557.
10. Amadori S, Petti MC, Mastrovincenzo C, Testa MG, Antonelli A, Mandelli F. Blast cell kinetics and prognosis in acute nonlympzocytic leukemia. Leukemia Res 1980; 4: 239-244.
11. Raza A, Maheshwari Y, Preisler HD. Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. Blood 1987; 69: 1647-1653.
12. Henschler R, Brennscheidt U, Mertelsmann R, Hermann F. Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-β-D-arabinofuranosylcytosine. Mol Pharmacol 1991; 39: 171-176.
13. Datta R, Kharbander S, Kufe D. Transcriptional and posttranscriptional regulation of HI histone gene expression by 1-β-D-arabinofuranosylcytosine. Mol Pharmacol 1992; 41: 64-68.
14. Brach MA, Kharbander SM, Herrmann F, Kufe D. Activation of the transcription factor kB in human KG-1 myeloid leukemia cells treated with 1-β-D-arabinofuranosylcytosine. Mol Pharmacol 1992; 41: 60-63.
15. Brach MA, Herrmann F, Kufe D. Activation of the AP-1 transcription factor by arabinofuranosylcytosine in myeloid leukemia cells. Blood 1992; 79: 728-734.